Education
About Us
Working with TipRanks
Follow Us
Aurora Cannabis (ACB)
NASDAQ:ACB
Earnings Data
Report Date
Jun 18, 2026TBA (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.26Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized material progress: top-line growth driven by a focused medical-cannabis strategy, strong high-single-digit revenue growth, healthy adjusted gross margins (62% consolidated; 69% medical), record international execution (Germany, Poland, Australia), positive adjusted EBITDA and free cash flow, and a conservative balance sheet with $154M cash and no cannabis-related debt. Management also announced strategic moves (exiting select Canadian consumer markets, divesting plant propagation stake, and an ATM up to $100M) designed to reallocate resources to higher-margin global medical markets. Offsetting this are deliberate shrinkage in the lower-margin Canadian consumer business (48% revenue decline by design), significant margin deterioration and write-offs in the plant propagation segment, higher SG&A to support international growth, modest YoY decline in adjusted EBITDA, and lower free cash flow versus the prior year. Overall, the operational and financial positives and the clear strategy to concentrate on a higher-margin global medical opportunity outweigh the operational headwinds and one-time/divestiture-related impacts, indicating constructive momentum and a cautiously positive outlook.Company Guidance
Consolidated Revenue Growth
Net revenue of $94.2M in fiscal Q3 (period ended Dec 31, 2025), up 7% year-over-year, driven by record global medical cannabis performance.
Strong Medical Cannabis Performance
Global medical cannabis revenue of $76.2M, up 12% YoY, with international medical cannabis up 17%; medical cannabis represented 81% of net revenue (versus 77% prior year) and ~95% of adjusted gross profit.
High and Improving Margins
Consolidated adjusted gross margin improved 100 basis points to 62%; medical cannabis adjusted gross margin held at 69%, supporting adjusted gross profit of $55.6M (up 6% YoY).
Profitability and Cash Generation
Adjusted EBITDA of $18.5M and adjusted net income of $7.2M in Q3; positive free cash flow of $15.5M; cash, cash equivalents and short-term investments totaled $154M and the company reported no cannabis business-related debt.
Global Commercial Execution and Regulatory Positioning
Market leadership across key international markets: #1 in Poland (2025), #2 share in Australia, continued share gains in Germany; ~90% of annual manufacturing capacity produced in European and TGA GMP-certified facilities; three Canadian facilities received renewed GMP certification for three years.
Strategic Actions to Improve Focus and Capital Flexibility
Announced selective exit from lower-margin Canadian consumer cannabis markets and divestiture of controlling stake in plant propagation (Bevo) to reallocate high-quality flower and resources to higher-margin global medical cannabis; filed $100M at-the-market (ATM) equity program to fund accretive initiatives including cultivation capacity and M&A.
Full-Year Outlook Indicates Growth
Annual global medical cannabis net revenue guidance of $269M–$281M (expected 10%–15% growth) and consolidated adjusted EBITDA guidance of $52M–$57M (expected 5%–10% growth), with management expecting margins to remain strong driven by sales mix and operational efficiencies.
ACB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ACB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 04, 2026 | $4.06 | $3.75 | -7.64% |
Nov 05, 2025 | $4.54 | $4.46 | -1.76% |
Aug 06, 2025 | $4.60 | $4.24 | -7.93% |
Jun 18, 2025 | $5.88 | $4.68 | -20.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Aurora Cannabis (ACB) report earnings?
Aurora Cannabis (ACB) is schdueled to report earning on Jun 18, 2026, TBA (Confirmed).
What is Aurora Cannabis (ACB) earnings time?
Aurora Cannabis (ACB) earnings time is at Jun 18, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ACB EPS forecast?
ACB EPS forecast for the fiscal quarter 2026 (Q4) is -0.04.
